| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Sepiapterin reductase; SPR; SPR |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E. coli-derived human SPR recombinant protein (Position: V36-K261). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
This antibody is intended for detection of SPR in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality/clone information, and detection modality.
Vendor notes: Boster Bio Anti-SPR Antibody Picoband® catalog # A00416-1. Tested in ELISA, WB applications. This antibody reacts with Human, Mouse. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Key elements and design rationale
- Antibody format: Rabbit Polyclonal Rabbit IgG
- Immunogen / epitope context: E. coli-derived human SPR recombinant protein (Position: V36-K261). (reported region: V36-K261).
- Molecular weight context: reported MW: 28 kDa; calculated MW: nan
- Reactivity: Human,Mouse
- Applications: ELISA, WB
As a polyclonal antibody, the reagent recognizes multiple epitopes on the target, which can improve detection robustness but may increase sensitivity to sample-dependent epitope changes.
Biological background
sepiapterin reductase. Sepiapterin reductase is an enzyme that in humans is encoded by the SPR gene. This gene encodes an aldo-keto reductase that catalyzes the NADPH-dependent reduction of pteridine derivatives and is important in the biosynthesis of tetrahydrobiopterin (BH4). Mutations in this gene result in DOPA-responsive dystonia due to sepiaterin reductase deficiency. A pseudogene has been identified on chromosome 1. Functional note: Catalyzes the final one or two reductions in tetra- hydrobiopterin biosynthesis to form 5,6,7,8-tetrahydrobiopterin. Reported localization: Cytoplasm.
Research relevance and current trends
- Amino Acid Metabolism: Researchers commonly examine how SPR relates to this theme using model systems and orthogonal readouts.
- Amino Acids: Researchers commonly examine how SPR relates to this theme using model systems and orthogonal readouts.
- Cancer: Researchers commonly examine how SPR relates to this theme using model systems and orthogonal readouts.
Common research applications
- Western blotting: compare relative SPR levels across conditions; band patterns may reflect isoforms and processing.
- ELISA-compatible use: when applicable, interpret signal as relative abundance across sample sets with consistent handling and dilution strategy.
Notes for experimental interpretation
- Specificity notes: No cross reactivity with other proteins.
- Cross-reactivity: No cross-reactivity with other proteins.
- Isoforms and PTMs: Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.
- Controls: Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD/KO samples when available.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
